Cough Syrup crisis: Rajasthan govt suspends drug controller, halts distribution of Kaysons Pharma medicines

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-10-04 07:31 GMT | Update On 2025-10-04 07:31 GMT

suspended

Jaipur: In a swift and decisive move, the Rajasthan government has suspended the state's drug controller and ordered the cessation of distribution for medicines manufactured by Jaipur-based Kaysons Pharma.

This follows reports linking contaminated cough syrup to the deaths of 11 children—nine in Madhya Pradesh and two in Rajasthan.

The Medical and Health Department confirmed that all 19 medicines produced by Kaysons Pharma have now been stopped from supply until further orders. In addition, the distribution of all other cough syrups containing Dextromethorphan has also been suspended.

The government has placed drug controller Rajaram Sharma under suspension for allegedly influencing the process of determining drug standards, the department said.

As per PTI, Chief Minister Bhajanlal Sharma has ordered a detailed probe into the matter along with effective action.

Following his instructions, an expert committee is being constituted to investigate the issue.

Health Minister Gajendra Singh also ordered an inquiry and measures to safeguard public interest, an official statement said.

Principal Secretary in the Medical and Health Department, Gayatri Rathore, said the Union government issued an advisory in 2021 against administering Dextromethorphan to children below four years.

The state has reiterated the advisory, while the Drug Controller General of India on Friday advised that the syrup should normally be given only to children above five years, and in no circumstances to those under two years of age.

Officials added that drugs which are potentially harmful to children and pregnant women will now carry clear warning labels.

According to the managing director of Rajasthan Medical Services Corporation Ltd (RMSCL), Pukhraj Sen, over 10,000 samples of Kaysons Pharma drugs have been tested since 2012, of which 42 failed the quality standards.

As a precaution, the supply of all 19 medicines manufactured by the company has been suspended.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Cough Syrup crisis: Rajasthan govt suspends drug controller, halts distribution of Kaysons Pharma medicines

Similar News

CDSCO panel nod to Bajaj Healthcare for Phase III clinical trials of insomnia drug Suvorexant

AstraZeneca Pharma India gains CDSCO permission for Enhertu in HER2-positive solid tumours

Lupin unveils Liraglutide Injection in US for diabetes

Police Have No Jurisdiction to Register FIR Under Drugs & Cosmetics Act: Delhi HC

MSD Pharma gets CDSCO panel nod for New Indications of Pembrolizumab in India

Cough Syrup Row: Rajasthan Practitioners Shift to Levocloperastine, Ambroxol Amid Dextromethorphan Concerns

Dummy Pharma Firms Under Probe for Rs 71 Crore Drug Scam in UP